Henry I. Miller

Biography: 

Henry I. Miller, MS, MD, was the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focused on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

During his time at the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He was a regulator contributor to Forbes.com and frequently appeared on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:

Topic

Type

Recent Commentary

Analysis and Commentary

Labeling Of Biotech Foods Is Unnecessary And Unconstitutional

by Henry I. Miller, Gregory Conkovia Forbes.com
Thursday, December 8, 2011

Product labeling that conveys essential information is important, but mandatory labeling of gene-spliced foods is a bad idea...

Analysis and Commentary

Solyndra And Siga Sagas A New Low In Obama's Crony Capitalism

by Henry I. Millervia Forbes.com
Wednesday, November 30, 2011

As repugnant as Nixon’s malfeasance was, the Watergate and Hoffa scandals didn’t cost the taxpayers anything (at least, until the investigations and prosecutions began). That can’t be said for Obama...

Analysis and Commentary

Hope or Hype for Personalized Medicine?

by Henry I. Millervia Project Syndicate
Thursday, November 24, 2011

If society is to derive the maximum benefit from personalized medicine – which will require companies to pursue it – regulators worldwide will need to adopt reasoned and reasonable policies...

Analysis and Commentary

NIH Reorganization Proposal Nothing To Crow About

by Henry I. Millervia Forbes.com
Wednesday, November 23, 2011

[ASU] President Michael Crow has suggested in a series of published commentaries that the [NIH], currently funded to the tune of $31 billion annually, has not served the nation well and should be reorganized. But his cure surely would be worse than the disease...

an image

Is the FDA Innovative?

by Henry I. Millervia Defining Ideas
Tuesday, November 22, 2011

An advocacy group, masquerading as a think tank, publishes a laughably inaccurate report.

In the News

Is the FDA Innovative?

by Henry I. Millervia Defining Ideas (Hoover Institution)
Tuesday, November 22, 2011

An advocacy group, masquerading as a think tank, publishes a laughably inaccurate report...

Analysis and Commentary

Do We Need An Invisible Surgeon General?

by Henry I. Millervia Forbes
Wednesday, November 9, 2011

Although some of the nation’s health care issues are complex and seem insoluble, others are relatively approachable...

In the News

A label we don't need

by Henry I. Miller, Drew L. Kershenvia Nature Biotechnology
Tuesday, November 8, 2011

The United Nations agency that sets food standards—the Codex Alimentarius—recently reached an impasse on the labeling of food containing products derived from recombinant DNA technology...

Analysis and Commentary

If Obama Were Serious About Stimulating The Economy, Regulatory Reform Would Make A Difference

by Henry I. Millervia Forbes.com
Thursday, November 3, 2011

Instead, we have gotten (and are getting) profligate spending and wasteful, unscientific, nanny-state policies that inhibit innovation, discourage R&D, blunt wealth creation and kill jobs...

Analysis and Commentary

Dying to Grow?

by Henry I. Millervia Project Syndicate
Tuesday, October 25, 2011

Studies that show an association between a factor and a health effect should be regarded as no more than a preliminary result that points researchers toward further research and analysis...

Pages